Targeted therapy for HER2-positive breast cancer

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help the cells to grow. They look for a specific feature of a cancer cell, attach to it, and destroy it. Only cancers with that feature will respond to the therapy.

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy. Hormonal therapy is a type of targeted therapy because it targets hormones that are active in cancer growth.

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 6 Min. Read |  1

Abemaciclib (Verzenio) is a targeted therapy approved by the Food and Drug Administration to treat hormone receptor-positive breast cancer.

Palbociclib (Ibrance), a targeted therapy, was the first CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 5 Min. Read |  3

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with metastatic, triple-negative breast cancer and people diagnosed with metastatic breast cancer that is hormone receptor-positive and HER2-negative.

Read More

 | 5 Min. Read |  8

Learn more about the different classes of targeted therapies for triple-negative breast cancer, the tumor biomarkers that tell us who may benefit from them, and how they work.

Trastuzumab deruxtecan (Enhertu) is an antibody drug conjugate approved to treat people with metastatic, HER2-positive, hormone receptor-negative breast cancer that has grown after at least two past treatments.

PARP inhibitors are targeted therapies used to treat certain breast, ovarian, pancreatic, and prostate cancers. In breast cancer, PARP inhibitors are FDA approved for people who were born with a mutation, or change, on the BRCA genes. The breast cancer can be early-stage or metastatic and must be HER2-negative.

Olaparib (Lynparza) is a targeted therapy approved by the Food and Drug Administration that is used to treat early-stage or metastatic breast cancer that is either hormone receptor-positive and HER2-negative, or triple-negative, in people with an inherited BRCA gene mutation who have already been treated with chemotherapy.